{"id":"NCT01499368","sponsor":"Boryung Pharmaceutical Co., Ltd","briefTitle":"A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients","officialTitle":"A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Koran Erosive Esophagitis Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-11","primaryCompletion":"2012-11","completion":"2012-11","firstPosted":"2011-12-26","resultsPosted":"2020-09-16","lastUpdate":"2025-01-15"},"enrollment":495,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Erosive Esophagitis"],"interventions":[{"type":"DRUG","name":"Lafutidine","otherNames":[]},{"type":"DRUG","name":"Famotidine","otherNames":[]},{"type":"DRUG","name":"Omeprazole","otherNames":[]}],"arms":[{"label":"Lafutidine","type":"EXPERIMENTAL"},{"label":"Famotidine","type":"ACTIVE_COMPARATOR"},{"label":"Omeprazole","type":"OTHER"}],"summary":"To evaluate the healing rate and safety of Lafutidine in erosive esophagitis","primaryOutcome":{"measure":"Recovery Rates of Reflux Esophagitis","timeFrame":"8 weeks","effectByArm":[{"arm":"Lafutidine","deltaMin":101,"sd":null},{"arm":"Famotidine","deltaMin":92,"sd":null},{"arm":"Omeprazole","deltaMin":126,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.05"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":4},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":165},"commonTop":["Nasopharyngitis","Abdominal pain","Dyspepsia","Headache","Alanine aminotransferase increased"]}}